Layth Mula-Hussain, Radiation Oncologist at BC Cancer, shared a post by Abdulaziz AlJassim, Thoracic and Sarcoma Medical Oncologist at The Ottawa Hospital, on X about a paper he coauthored with colleagues, published in the Journal of Immunotherapy and Precision Oncology:
“Delighted to be part of this important research work that is needed in our MENA region about molecular markers in lung cancer. Thank you, Dr. Abdulaziz AlJassim, for your insights and leadership.”
Quoting Abdulaziz AlJassim‘s post:
“Proud to share our GCC Lung Oncology Group publication in the JIPO Editors
A systematic review + expert opinion on NSCLC in the MENA region highlights the prevalence of driver mutations in NSCLC across the MENA region EGFR 24% | ALK 7.9% | KRAS 19.7% This work underscores the importance of region-specific strategies.”
Fawzi Abu Rous, Thoracic medical oncologist at Henry Ford Health, shared this post too, adding:
“Very important data coming from #MENA on driver mutations in #NSCLC showing EGFR, ALK, and KRAS in 24%, 7.9% and 19.7%, respectively. I hope that regulatory authorities will act on this data by expanding access to molecular testing and targeted therapies
Congratulations to the authors, Abdulaziz AlJassim and Layth Mula-Hussain, on this very important work.”
Title: Prevalence of Molecular Mutations in Non–Small Cell Lung Cancer and Current Treatment Approaches in the MENA Region: Systematic Review and Expert Opinion
Authors: AbdulAziz AlJassim, Aladdin Kanbour, Fathi Azribi, Muath AlNassar, Riadh Mohsen, Sahar Dawod, Selvaraj Giri, Michael Nasr Kamal, Ali AlJabban, Layth Mula-Hussain, Bader Alshamsan, Emad Anwar
You can read the full article on the Journal of Immunotherapy and Precision Oncology.
More posts featuring Layth Mula-Hussain on OncoDaily.